A Long-term Safety Study of Infliximab (Remicade)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00261976|
Recruitment Status : Completed
First Posted : December 6, 2005
Last Update Posted : March 18, 2014
|Condition or disease||Intervention/treatment|
|Arthritis, Rheumatoid Crohn Disease Psoriasis||Drug: Infliximab (Remicade)|
|Study Type :||Observational|
|Actual Enrollment :||2971 participants|
|Official Title:||Long-term Safety Follow-up of REMICADE (RESULTS)|
|Study Start Date :||February 2002|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||March 2012|
Patients in infliximab clinical studies
All patients enrolled in selected Centocor sponsored infliximab clinical studies.
Drug: Infliximab (Remicade)
This is an non-interventional study. Participants took the study product as part of their medical routine.
- Number of patients with each of the following long-term safety events [ Time Frame: Five years ]Number of patients with each of the following long-term safety events: serious infections, new malignancies, new autoimmune diseases, death, or delayed hypersensitivity (serum sickness-like) reactions.
- Number of patients with malignancies by malignancy type [ Time Frame: Five years ]Number of patients with malignancies by malignancy type (ie, lymphoma, nonmelanoma skin cancers, other malignancies).
- Number of patients with serious infections by type of infection [ Time Frame: Five years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00261976
Show 212 Study Locations
|Study Director:||Centocor, Inc. Clinical Trial||Centocor, Inc.|